Shanghai Junshi Biosciences Co (SHSE:688180) Other Stockholders Equity: ¥437 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:688180 Shanghai Junshi Biosciences Co Ltd SHSE:688180
66 GF Score
Price ¥38.91
GF Value ¥45.41
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Shanghai Junshi Biosciences Co Other Stockholders Equity?

Shanghai Junshi Biosciences Co SHSE:688180 -0.84% 66 Other Stockholders Equity is ¥437 Mil as of Dec. 2025. GuruFocus rates SHSE:688180 with a GF Score™ of 66/100 and a GF Value™ of ¥45.41 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Shanghai Junshi Biosciences Co's Other Stockholders Equity for the quarter that ended in Dec. 2025 was ¥437 Mil.

Shanghai Junshi Biosciences Co's quarterly Other Stockholders Equity declined from Dec. 2024 (¥364 Mil) to Jun. 2025 (¥352 Mil) but then increased from Jun. 2025 (¥352 Mil) to Dec. 2025 (¥437 Mil).

Shanghai Junshi Biosciences Co's annual Other Stockholders Equity declined from Dec. 2023 (¥456 Mil) to Dec. 2024 (¥364 Mil) but then increased from Dec. 2024 (¥364 Mil) to Dec. 2025 (¥437 Mil).

Shanghai Junshi Biosciences Co Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Shanghai Junshi Biosciences Co's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shanghai Junshi Biosciences Co Other Stockholders Equity Chart

Shanghai Junshi Biosciences Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7,050.15 746.00 456.24 364.26 436.68

Shanghai Junshi Biosciences Co Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 456.24 431.90 364.26 351.84 436.68
SHSE:688180
66GF Score
Shanghai Junshi Biosciences Co Ltd SHSE:688180
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Shanghai Junshi Biosciences Co Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of ¥437 Mil mean?
Shanghai Junshi Biosciences Co (SHSE:688180) has a Other Stockholders Equity of ¥437 Mil as of Dec. 2025. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Shanghai Junshi Biosciences Co and its competitors.
Is Shanghai Junshi Biosciences Co's Other Stockholders Equity too high?
Shanghai Junshi Biosciences Co's current Other Stockholders Equity is ¥437 Mil. Overall, Shanghai Junshi Biosciences Co has a GF Score™ of 66/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Junshi Biosciences Co's Other Stockholders Equity compare to VRTX and REGN?
Shanghai Junshi Biosciences Co's Other Stockholders Equity of ¥437 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Biotechnology company?
A good Other Stockholders Equity depends on the Biotechnology industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Shanghai Junshi Biosciences Co and its competitors. Shanghai Junshi Biosciences Co's current Other Stockholders Equity is ¥437 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Junshi Biosciences Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Junshi Biosciences Co (SHSE:688180) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥45.41, compared to a current price of ¥38.91 — trading 14.3% below its estimated fair value. The current Other Stockholders Equity is ¥437 Mil. Shanghai Junshi Biosciences Co's overall GF Score™ is 66/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Shanghai Junshi Biosciences Co (SHSE:688180), the current Other Stockholders Equity is ¥437 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Shanghai Junshi Biosciences Co (SHSE:688180) Overvalued in 2026?

Based on GuruFocus' analysis, Shanghai Junshi Biosciences Co stock appears to be undervalued. The current stock price of ¥38.91 is trading 14.3% below its estimated GF Value™ of ¥45.41. GuruFocus considers Shanghai Junshi Biosciences Co to be Modestly Undervalued.

Key valuation signals for SHSE:688180:

  • Other Stockholders Equity: ¥437 Mil
  • GF Value™: ¥45.41 vs. price of ¥38.91 (14.3% below fair value)
  • GF Score™: 66/100 with 4 warning signs

No single metric tells the full story. See the SHSE:688180 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Shanghai Junshi Biosciences Co Business Description

Other Exchanges SHJBF:USA01877:Hong Kong
Address No. 987 Cai Lun Road, Level 4, China (Shanghai) Pilot Free Trade Zone, Shanghai, CHN
Shanghai Junshi Biosciences Co Ltd is mainly involved in the discovery, development, and commercialisation of therapeutic drugs. It focuses on the development and commercialization of several kinds of drugs, ranging from monoclonal antibodies to various drug modalities, including small molecules, ADCs, bi-specific or multi-specific antibodies, fusion proteins, nucleic acid drugs, and vaccines, as well as the exploration of next-generation therapies, including those for cancer and autoimmune diseases. The Group's portfolio includes commercialized drugs such as Tuoyi, Junmaikang, Mindewei, and Junshida, as well as products in clinical studies or in the marketing application stage. Geographically, it derives maximum revenue from Mainland China, and the rest from USA, India, and other markets.
66GF Score

Get the complete analysis for SHSE:688180

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥38.91
Price
¥45.41
GF Value